{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/REGN/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-16T08:33:58.695Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":8466,"canonical_name":"REGENERON PHARMACEUTICALS, INC.","cik":"0000872589","uei":null,"lei":null,"duns":null,"ticker":"REGN"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"clinical":55,"sec":10},"count":65,"timeline":[{"ts":"2026-10-15","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07876492","excerpt":"[\"Secondary Stroke\"]","importance":60},{"ts":"2026-10-15","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Healthy Adult Participants Trial Comparing Different Cenvacibart Presentations","security_title":"PHASE1","status":"NOT_YET_RECRUITING","accession_number":"NCT07876505","excerpt":"[\"Healthy Volunteers\"]","importance":30},{"ts":"2026-10-08","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07626411","excerpt":"[\"Atrial Fibrillation (AF)\"]","importance":60},{"ts":"2026-10-07","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors","security_title":"PHASE1,PHASE2","status":"NOT_YET_RECRUITING","accession_number":"NCT07863024","excerpt":"[\"Advanced Solid Tumors\"]","importance":45},{"ts":"2026-10-06","kind":"sec.filing","form_type":"8-K","title":"8-K — REGENERON PHARMACEUTICALS, INC. — 2026-10-06","url_slug":"/sec/cik-0000872589/8-k/0001104659-26-113895","accession_number":"0001104659-26-113895","importance":35},{"ts":"2026-10-06","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07759167","excerpt":"[\"End-Stage Kidney Disease (ESKD)\"]","importance":30},{"ts":"2026-10-06","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants With Graves' Disease (GD)","security_title":"PHASE1","status":"NOT_YET_RECRUITING","accession_number":"NCT07861152","excerpt":"[\"Graves' Disease\"]","importance":30},{"ts":"2026-10-02","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07854782","excerpt":"[\"Metabolic Dysfunction-Associated Steatotic Liver Disease\",\"MASLD\"]","importance":60},{"ts":"2026-09-30","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants","security_title":"PHASE1,PHASE2","status":"NOT_YET_RECRUITING","accession_number":"NCT07850921","excerpt":"[\"Metastatic Castration-Resistant Prostate Cancer\",\"mCRPC\"]","importance":45},{"ts":"2026-09-30","kind":"sec.filing","form_type":"8-K","title":"8-K — REGENERON PHARMACEUTICALS, INC. — 2026-09-30","url_slug":"/sec/cik-0000872589/8-k/0001104659-26-112340","accession_number":"0001104659-26-112340","importance":35},{"ts":"2026-09-29","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07697599","excerpt":"[\"Venous Thromboembolism (VTE)\"]","importance":60},{"ts":"2026-09-29","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07685808","excerpt":"[\"Overweight or Obesity\"]","importance":45},{"ts":"2026-09-28","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT07675824","excerpt":"[\"Primary Open Angle Glaucoma (POAG)\",\"Ocular Hypertension (OHT)\"]","importance":45},{"ts":"2026-09-25","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)","security_title":"PHASE4","status":"RECRUITING","accession_number":"NCT07609940","excerpt":"[\"Relapsed/Refractory Multiple Myeloma (RRMM)\"]","importance":25},{"ts":"2026-09-22","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Trial of ALN-6457 in Adult Participants With Symptomatic Prion Disease (PrD)","security_title":"PHASE1,PHASE2","status":"NOT_YET_RECRUITING","accession_number":"NCT07832370","excerpt":"[\"Prion Disease\"]","importance":45},{"ts":"2026-09-21","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity","security_title":"PHASE2","status":"NOT_YET_RECRUITING","accession_number":"NCT07830329","excerpt":"[\"Hidradenitis Suppurativa\"]","importance":45},{"ts":"2026-09-09","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)","security_title":"PHASE2","status":"NOT_YET_RECRUITING","accession_number":"NCT07808515","excerpt":"[\"Locally Advanced Basal Cell Carcinoma\"]","importance":45},{"ts":"2026-08-21","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Compassionate Use of Vonsetamig","security_title":null,"status":"AVAILABLE","accession_number":"NCT07780110","excerpt":"[\"Plasma Cell Mediated\",\"Antibody Mediated\"]","importance":25},{"ts":"2026-08-20","kind":"sec.filing","form_type":"N-PX","title":"N-PX — REGENERON PHARMACEUTICALS, INC. — 2026-08-20","url_slug":"/sec/cik-0000872589/n-px/0001104659-26-099230","accession_number":"0001104659-26-099230","importance":30},{"ts":"2026-08-12","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07675811","excerpt":"[\"Allergic Conjunctivitis\"]","importance":60},{"ts":"2026-08-07","kind":"sec.filing","form_type":"13F-HR","title":"13F-HR — REGENERON PHARMACEUTICALS, INC. — 2026-08-07","url_slug":"/sec/cik-0000872589/13f-hr/0001104659-26-092709","accession_number":"0001104659-26-092709","importance":30},{"ts":"2026-08-07","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation","security_title":"PHASE1","status":"NOT_YET_RECRUITING","accession_number":"NCT07753148","excerpt":"[\"Clonal Cytopenia of Undetermined Significance (CCUS)\",\"Low-Risk Myelodysplastic Syndrome (LR-MDS)\"]","importance":30},{"ts":"2026-07-30","kind":"sec.filing","form_type":"10-Q","title":"10-Q — REGENERON PHARMACEUTICALS, INC. — 2026-07-30","url_slug":"/sec/cik-0000872589/10-q/0000872589-26-000025","accession_number":"0000872589-26-000025","importance":45},{"ts":"2026-07-30","kind":"sec.filing","form_type":"8-K","title":"8-K — REGENERON PHARMACEUTICALS, INC. — 2026-07-30","url_slug":"/sec/cik-0000872589/8-k/0000872589-26-000023","accession_number":"0000872589-26-000023","importance":35},{"ts":"2026-07-17","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study to Identify and Characterize Adults and Pediatric Participants With Cat and/or Birch Allergy","security_title":null,"status":"NOT_YET_RECRUITING","accession_number":"NCT07710846","excerpt":"[\"Conjunctivitis Allergic\"]","importance":25},{"ts":"2026-07-06","kind":"sec.filing","form_type":"8-K","title":"8-K — REGENERON PHARMACEUTICALS, INC. — 2026-07-06","url_slug":"/sec/cik-0000872589/8-k/0001104659-26-080562","accession_number":"0001104659-26-080562","importance":35},{"ts":"2026-07-02","kind":"sec.form144","reporter":"Arthur F. Ryan","title":"Director","shares":400,"usd_value":249888,"security_title":"Common Stock","approx_sale_date":"2026-07-02","accession_number":"0001968582-26-000693","importance":40.0499776},{"ts":"2026-07-02","kind":"sec.insider.s","reporter":"RYAN ARTHUR F","title":null,"shares":200,"price_per_share":650.15,"usd_value":130030,"security_title":"Common Stock","importance":35.13003},{"ts":"2026-06-17","kind":"sec.filing","form_type":"8-K","title":"8-K — REGENERON PHARMACEUTICALS, INC. — 2026-06-17","url_slug":"/sec/cik-0000872589/8-k/0001104659-26-075127","accession_number":"0001104659-26-075127","importance":35},{"ts":"2026-06-08","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)","security_title":"PHASE2","status":"NOT_YET_RECRUITING","accession_number":"NCT07631637","excerpt":"[\"Metabolic Dysfunction-Associated Steatohepatitis (MASH)\"]","importance":45},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer","security_title":"PHASE3","status":"COMPLETED","accession_number":"NCT03409614","excerpt":"[\"Non-small Cell Lung Cancer\"]","importance":70},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma","security_title":"PHASE1,PHASE2","status":"NOT_YET_RECRUITING","accession_number":"NCT07594106","excerpt":"[\"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\"Clear Cell Renal Cell Carcinoma (ccRCC)\"]","importance":45},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity","security_title":"PHASE1","status":"NOT_YET_RECRUITING","accession_number":"NCT07594093","excerpt":"[\"Overweight or Obesity\"]","importance":30},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07154745","excerpt":"[\"Paroxysmal Nocturnal Hemoglobinuria\"]","importance":60},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization","security_title":"PHASE4","status":"NOT_YET_RECRUITING","accession_number":"NCT07587658","excerpt":"[\"Chronic Obstructive Pulmonary Disease (COPD)\"]","importance":25},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT05828511","excerpt":"[\"Multiple Myeloma\"]","importance":45},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06787612","excerpt":"[\"Ovarian Cancer\",\"Fallopian Tube Cancer\",\"Primary Peritoneal Cancer\"]","importance":45},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe","security_title":null,"status":"RECRUITING","accession_number":"NCT05363319","excerpt":"[\"Non-small Cell Lung Cancer\"]","importance":25},{"ts":"2026-05-11","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06230224","excerpt":"[\"B-Cell Non-Hodgkin Lymphoma (B-NHL)\"]","importance":60},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy","security_title":"PHASE3","status":"COMPLETED","accession_number":"NCT06602726","excerpt":"[\"Allergic Conjunctivitis\"]","importance":70},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07222761","excerpt":"[\"Relapsed and/or Refractory Multiple Myeloma (RRMM)\"]","importance":60},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06299098","excerpt":"[\"Obesity\"]","importance":45},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT03564340","excerpt":"[\"Recurrent Ovarian Cancer\",\"Recurrent Fallopian Tube Cancer\",\"Recurrent Primary Peritoneal Cancer\",\"Recurrent Endometrial Cancer\",\"Endometrial Cancer\",\"Low-grade Serous Ovarian Cancer\"]","importance":45},{"ts":"2026-05-07","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07154290","excerpt":"[\"Advanced/Metastatic Non-Small Cell Lung Cancer\"]","importance":45},{"ts":"2026-05-07","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT05519475","excerpt":"[\"Metabolic Dysfunction-Associated SteatoHepatitis (MASH)\"]","importance":45},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07213778","excerpt":"[\"Symptomatic Venous Thromboembolism (VTE)\"]","importance":60},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07220785","excerpt":"[\"Generalized Lipodystrophy\"]","importance":60},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06246916","excerpt":"[\"Melanoma\"]","importance":60},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05557591","excerpt":"[\"Advanced Non-Small Cell Lung Cancer\"]","importance":45},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT05788536","excerpt":"[\"Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)\"]","importance":45},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT06369467","excerpt":"[\"Food Allergy\"]","importance":30},{"ts":"2026-05-04","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06593600","excerpt":"[\"Postural Orthostatic Tachycardia Syndrome (POTS)\"]","importance":45},{"ts":"2026-05-04","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)","security_title":"PHASE1,PHASE2","status":"COMPLETED","accession_number":"NCT04083534","excerpt":"[\"Relapsed Multiple Myeloma\",\"Refractory Multiple Myeloma\"]","importance":45},{"ts":"2026-05-04","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT05685173","excerpt":"[\"B-cell Non-Hodgkins Lymphoma (B-NHL)\"]","importance":30},{"ts":"2026-04-30","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05133531","excerpt":"[\"Paroxysmal Nocturnal Hemoglobinuria\"]","importance":60},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07430956","excerpt":"[\"Atrial Fibrillation (AF)\"]","importance":60},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07431086","excerpt":"[\"Overweight or Obesity\"]","importance":45},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06292780","excerpt":"[\"Relapsed/Refractory Systemic Light Chain Amyloidosis\"]","importance":45},{"ts":"2026-04-28","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07318597","excerpt":"[\"Pulmonary Arterial Hypertension (PAH)\"]","importance":45},{"ts":"2026-04-27","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06836609","excerpt":"[\"Metabolic Dysfunction-Associated Steatotic Liver Disease\",\"Metabolic Dysfunction-Associated Steatohepatitis\"]","importance":45},{"ts":"2026-04-22","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05352672","excerpt":"[\"Melanoma\"]","importance":60},{"ts":"2026-04-22","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06585410","excerpt":"[\"Cutaneous Squamous Cell Carcinoma (CSCC)\"]","importance":60},{"ts":"2026-04-22","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma","security_title":"PHASE4","status":"RECRUITING","accession_number":"NCT06572228","excerpt":"[\"Asthma\"]","importance":25},{"ts":"2026-04-21","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy","security_title":"PHASE3","status":"COMPLETED","accession_number":"NCT06602739","excerpt":"[\"Allergic Conjunctivitis\"]","importance":70},{"ts":"2026-04-20","kind":"clinical.trial","reporter":"Regeneron Pharmaceuticals","title":"Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT03761108","excerpt":"[\"Multiple Myeloma\"]","importance":45}]}